Resistance for other antibiotics such as sulbactam
ampicillin 22 (68.
Other antibiotics tested were: imipenem, meropenem, tazobactum, amikacin, cefoperazone sulbactam
, gentamicin, cefepime, ceftazidime, co-amoxiclav, ticarcillin, aztreonam, cefoperazone, co-trimoxazole, cefotaxime, cefixime, ceftriaxone, pipemidic acid and ampicillin.
ETX2514 exhibited particularly promising activity in combination with sulbactam
against Acinetobacter baumannii, including hard-to-treat carbapenem-resistant and colistin-resistant strains, and with imipenem against carbapenem-resistant Enterobacteriaceae (CRE) and Pseudomonas aeruginosa.
baumannii (MIC[sub]90 64–128 mg/L), in which activity is due to sulbactam
alone [Table 2].
cefixime, ceftazidime, co-trimoxazole, ciprofloxacin, gentamicin, amikacin, cefoperazone + sulbactam
, piperacillin + tazobactam, meropenem, polymyxin - B, and aztreonam were used.
4%, respectivamente, debido a que ambas aminopenicilinas estaban asociadas a un agente inhibidor de betalactamasas, como son el acido clavulanico y el sulbactam
Although rare, pandrug resistant isolates have also been described, which show resistance to sulbactam
, minocycline, tigecycline and colistin.
has been shown to enhance the in vitro spectrum of cefoperazone, [sup], and the combination is active against a great proportion of many clinical pathogens including multidrug-resistant GNBs (MDRGNBs).
Entasis Therapeutics, a developer of innovative cures for serious drug-resistant bacterial infections, revealed on Wednesday that it has initiated a Phase 1 clinical study of ETX2514, its next-generation beta-lactamase inhibitor that is initially being developed in combination with sulbactam
, a beta-lactam with activity against Acinetobacter baumannii.
3,5,16] Colistin is usually combined with sulbactam
, cephalosporins, carbapenems, piperacillin-tazobactam, monobactams, aminoglycosides, fluoroquinolones, rifampin, tetracyclines and tigecycline.
In recent days the use of two different antibiotics in combination has been explored as a successful therapeutic option [16-18], Sulbactam
and tazobactam are an irreversible inhibitors of p-lactamase and they are given in combination with p-lactam antibiotics to inhibit p-lactamase , Sulbactam
and tazobactam are considered having intrinsic activity against Acinetobacter spp, and can be explored as a therapeutic option in combination with the drug of choice, which are being limited day by day, Sulbactam
has been used in combination with ampicillin and cefoperazone for the treatment of Acinetobactor spp.
In group 2 (n= 13), injection Amoxycillin and Sulbactam
@ 10 mg / kg b.